\-\ Texto\\:\\ \ \(0\)\
\-\ hiv\\ \\(\\+\\)\ \(0\)\
\-\ hbv\\ dna\\ \\(\\+\\)\ \(0\)\
\-\ alpha\\-feto\\ n\\/a\ \(0\)\
\-\ chemotherapy\ \(327\)\
\-\ surgery\ \(977\)\
\-\ 1\\.heterogeneously\\ enhancing\\ tumor\\ involving\\ the\\ entire\\ right\\ lobe\\ of\\ the\\ liver\\ and\\ shrunken\\ nodular\\ appeareance\\ of\\ the\\ liver\ \(0\)\
\-\ 2\\.marked\\ ascites\ \(0\)\
\-\ 3\\.non\\-enhancement\\ of\\ the\\ portal\\ vein\ \(0\)\
\-\ 4\\.enlarged\\ collateral\\ esophageal\\ varices\ \(0\)\
\-\ 5\\.superficial\\ soft\\ tissue\\ swelling\ \(0\)\
\-\ hepatocellular\\ carcinoma\\,\\ with\\ portal\\ hypertension\\,\\ portal\\ vein\\ thrombosis\\,\\ esophageal\\ varices\\,\\ \\"caput\\ medusa\\"\\,\\ ascites\ \(0\)\
\-\ metastasis\ \(206\)\
\-\ hepatic\\ adenoma\ \(5\)\
\-\ focal\\ nodular\\ hyperplasia\ \(9\)\
\-\ cavernous\\ hemangioma\ \(14\)\
\-\ 44\\ year\\-old\\ male\\ with\\ known\\ history\\ of\\ hepatocellular\\ carcinoma\\ with\\ new\\ onset\\ of\\ ascites\\.\ \(1\)\
\-\ multiple\\ findings\\ on\\ ct\\ images\\ secondary\\ to\\ hcc\\.\ \(0\)\
\-\ development\\ of\\ hcc\\ withcorrelation\\ to\\ history\\ of\\ hiv\\ and\\ hvb\\ as\\ risk\\ factors\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ascites\\:\\ 0\\.3200193873814916\ \(0\)\
\-\ portal\\:\\ 0\\.2969101879657763\ \(0\)\
\-\ varices\\:\\ 0\\.2658110921819837\ \(0\)\
\-\ hcc\\:\\ 0\\.23919759734728638\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.21264216447872575\ \(0\)\
\-\ hiv\\:\\ 0\\.20455104845924468\ \(0\)\
\-\ esophageal\\:\\ 0\\.17673061439073107\ \(0\)\
\-\ appeareance\\:\\ 0\\.1653898676390393\ \(0\)\
\-\ withcorrelation\\:\\ 0\\.1653898676390393\ \(0\)\
\-\ hvb\\:\\ 0\\.1653898676390393\ \(0\)\
\-\ nodular\\:\\ 0\\.16471570732709306\ \(0\)\
\-\ hbv\\:\\ 0\\.15803884805493518\ \(0\)\
\-\ medusa\\:\\ 0\\.1487776586473271\ \(0\)\
\-\ vein\\:\\ 0\\.1482593126385934\ \(0\)\
\-\ shrunken\\:\\ 0\\.1454721970729635\ \(0\)\
\-\ liver\\:\\ 0\\.14268673350557265\ \(0\)\
\-\ of\\:\\ 0\\.14167080269069166\ \(0\)\
\-\ caput\\:\\ 0\\.1362110076653554\ \(0\)\
\-\ dna\\:\\ 0\\.13145438420330624\ \(0\)\
\-\ carcinoma\\:\\ 0\\.12372142126343941\ \(0\)\
\-\ collateral\\:\\ 0\\.09897006265525876\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.09428509875311306\ \(0\)\
\-\ entire\\:\\ 0\\.0941064781451922\ \(0\)\
\-\ 44\\:\\ 0\\.09146474558618747\ \(0\)\
\-\ cavernous\\:\\ 0\\.08970887324765067\ \(0\)\
\-\ factors\\:\\ 0\\.08748074907889876\ \(0\)\
\-\ hemangioma\\:\\ 0\\.08699401259566306\ \(0\)\
\-\ development\\:\\ 0\\.08549673049726947\ \(0\)\
\-\ thrombosis\\:\\ 0\\.08431974918562499\ \(0\)\
\-\ the\\:\\ 0\\.08254353720088696\ \(0\)\
\-\ adenoma\\:\\ 0\\.08245106643984097\ \(0\)\
\-\ hepatic\\:\\ 0\\.08235785366354653\ \(0\)\
\-\ hypertension\\:\\ 0\\.07913003608388322\ \(0\)\
\-\ history\\:\\ 0\\.07902426786872213\ \(0\)\
\-\ metastasis\\:\\ 0\\.07579865621339385\ \(0\)\
\-\ risk\\:\\ 0\\.0738949624910669\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.0734344972307791\ \(0\)\
\-\ involving\\:\\ 0\\.07243931690234393\ \(0\)\
\-\ new\\:\\ 0\\.07154707502011166\ \(0\)\
\-\ swelling\\:\\ 0\\.06960620265742884\ \(0\)\
\-\ known\\:\\ 0\\.06695667265085983\ \(0\)\
\-\ onset\\:\\ 0\\.06640842821797172\ \(0\)\
\-\ enhancing\\:\\ 0\\.06478597803661551\ \(0\)\
\-\ focal\\:\\ 0\\.061860710631719704\ \(0\)\
\-\ secondary\\:\\ 0\\.06129918725375209\ \(0\)\
\-\ with\\:\\ 0\\.06075233612637474\ \(0\)\
\-\ lobe\\:\\ 0\\.05976538841770613\ \(0\)\
\-\ surgery\\:\\ 0\\.05560255372993908\ \(0\)\
\-\ soft\\:\\ 0\\.05505819878329073\ \(0\)\
\-\ tissue\\:\\ 0\\.05425139847537799\ \(0\)\
\-\ tumor\\:\\ 0\\.054094259072978275\ \(0\)\
\-\ to\\:\\ 0\\.05170921009434545\ \(0\)\
\-\ findings\\:\\ 0\\.051041539542134216\ \(0\)\
\-\ multiple\\:\\ 0\\.05058459756780771\ \(0\)\
\-\ images\\:\\ 0\\.04783828045780921\ \(0\)\
\-\ male\\:\\ 0\\.04604622079178447\ \(0\)\
\-\ and\\:\\ 0\\.04274063659167348\ \(0\)\
\-\ as\\:\\ 0\\.041547176193340446\ \(0\)\
\-\ ct\\:\\ 0\\.039372672900124715\ \(0\)\
\-\ right\\:\\ 0\\.03428775472206455\ \(0\)\
\-\ on\\:\\ 0\\.03123438346061209\ \(0\)\
